Fortum, 2 g

Urinary tract infections, Biliary tract infections, Osteomyelitis, Infectious diseases, Bronchitis, Skin infections, Respiratory tract infections, Pneumonia

Severe infections, including nosocomial infections (septicemia, bacteremia, peritonitis, meningitis, infections in immunocompromised patients, infected burns);

Respiratory tract infections and infections in cystic fibrosis patients;

ENT infections; urinary tract infections;

Skin and soft tissue infections;

Gastrointestinal, biliary and abdominal infections;

bone and joint infections;

dialysis-related infections;

Prevention of infectious complications in prostate surgeries (transurethral resection).

Active ingredient

Composition

1 vial contains ceftazidime (in pentahydrate form) 2 g.

Auxiliary substances:

Sodium carbonate (anhydrous),

Carbon dioxide.

How to take, the dosage

Iv or IM deeply into the upper outer quadrant of the greater gluteal muscle or the lateral thigh.

The ceftazidime solution can be injected directly into a vein or into a tube of an infusion system.

The dose of the drug is adjusted individually depending on the severity of the disease, localization, type of causative agent and its sensitivity to the drug, as well as the patient’s age and renal function.

The maximum daily dose is 6 g.

Interaction

The simultaneous administration of ceftazidime in high doses and nephrotoxic drugs may have adverse effects on renal function.

“Loop” diuretics, aminoglycosides, vancomycin , clindamycin decrease clearance of ceftazidime, resulting in an increased risk of nephrotoxic effects.

The bacteriostatic antibiotics (including chloramphenicol ) reduce the effect of beta-lactam antibiotics.

Special Instructions

In case of allergic reaction to ceftazidime the drug should be withdrawn immediately, in severe cases adrenaline, hydrocortisone, antihistamines and other emergency measures may be required.

When concomitant administration of high-dose cephalosporins with nephrotoxic drugs such as aminoglycosides and diuretics (furosemide), renal function should be monitored.

Because ceftazidime is excreted through the kidneys, in patients with renal impairment its dose should be reduced according to the degree of renal impairment. Prolonged use of broad-spectrum antibiotics, including ceftazidime, may lead to increased growth of insensitive microorganisms (e.g. Candida, Enterococci), and discontinuation of treatment or appropriate therapy may be required.

The patient’s condition must be constantly evaluated during treatment. Some initially sensitive strains of Enterobacter and Serratia may develop resistance when treated with ceftazidime; therefore, periodic antibiotic sensitivity testing should be performed when treating infections caused by these microorganisms.

Ceftazidime has no effect on the results of glucose determination in urine by enzymatic methods, but may have a weak effect on the results of methods based on copper reduction (Benedict, Fehling, Clinitest). Ceftazidime does not affect the quantitative determination of creatinine by the alkaline-picrine method (Jaffe method).

Contraindications

Hypersensitivity to ceftazidime or any other component of Fortum and to other cephalosporin antibiotics, penicillins.

Side effects

Local reactions: phlebitis or thrombophlebitis when Fortum is injected intravenously; pain, burning, thickening at the injection site when injected intravenously.

Hypersensitivity reactions: patchy-papular rash, urticaria, fever, pruritus, angioedema, bronchospasm, decreased BP, exudative erythema multiforme (including Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell’s syndrome).

Gastrointestinal disorders: diarrhea, nausea, vomiting, abdominal pain; oropharyngeal candidiasis, colitis. As with other cephalosporins, colitis may be caused by Clostridium difficile and appear as pseudomembranous colitis.

Urogenital system disorders: candidiasis vaginitis, impaired renal function.

Hepatobiliary system and pancreatic disorders: very rare – jaundice.

CNS disorders: headache, dizziness, paresthesias, taste disorders. In patients with renal failure more often than in other patients neurological disorders are noted, including tremor, myoclonia, convulsions, encephalopathy, coma.

Laboratory parameters: eosinophilia, false positive direct Coombs reaction, thrombocytosis, increased activity of liver enzymes – ALT, AST, LDH, gamma-glutamyl transpeptidase and ALP. Sometimes there is a transient increase in blood levels of urea, urea nitrogen and/or creatinine.

Hematopoietic organs: leukopenia, neutropenia, agranulocytosis, thrombocytopenia, lymphocytosis, hemolytic anemia.

Overdose

Symptoms: neurological disorders (including encephalopathy, seizures, Coma ).

Treatment: symptomatic and supportive therapy. Serum ceftazidime concentration may be decreased with hemodialysis or peritoneal dialysis.

Pregnancy use

With caution.

Similarities